SPAR – a randomised, placebo-controlled phase II trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer: an AGITG clinical trial
Pharmacology, Toxicology and Pharmaceutical Science
3
5%
Nursing and Health Professions
2
4%
Engineering
2
4%
Other
8
14%
Unknown
19
33%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 May 2020.
All research outputs
#17,113,100
of 25,837,817 outputs
Outputs from BMC Cancer
#4,232
of 9,083 outputs
Outputs of similar age
#283,729
of 469,525 outputs
Outputs of similar age from BMC Cancer
#79
of 190 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. This one is in the 31st percentile – i.e., 31% of other outputs scored the same or lower than it.
So far Altmetric has tracked 9,083 research outputs from this source. They receive a mean Attention Score of 4.8. This one is in the 48th percentile – i.e., 48% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 469,525 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 190 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.
